Strides Pharma Science announced its consolidated financial results for the quarter (Q4FY25) and full year (FY25) ended March 31, 2025. The company reported a five-fold jump in its the net profit to Rs 113 crore in Q4 FY25 from Rs 24.2 crore a year earlier, while the revenue climbed by 17% YoY to Rs 1,190.4 crore. EBITDA grew 22% on year to Rs 218 crore, with margins expanding 75 basis points to 18.3%.

The company’s US revenue surged 23.2% YoY to $77 million, supported by new product launches and a stable base business. 

For the full year FY25, net profit soared 12x to Rs 345 crore, with revenue up 17.2% at Rs 4565.3 crore. EBITDA for the year rose 36.8% to Rs 802.8 crore, and the EBITDA margin improved by 252 basis points to 17.6%.

Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, "We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering Rs. 802.8 crore in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger.

We reduced Net debt by Rs. 512.8 crore, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given. The US business recorded $291million in revenue, representing 21.8% YoY growth and exceeding the outlook. This was propelled by new product launches, steady base business, and a strong commercial execution framework. We also delivered an operating PAT of Rs. 344.7 crore for FY25, reflecting continued focus on profitability.

The Board has recommended a dividend of ₹4 per share for FY25, reflecting our strong financial performance. As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders."